Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it ...

Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...

First Commercial mRNA Vaccine Approval Expected By 2029 Says Kuick ResearchDelhi, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Global ...

Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

Vaccine stocks received a major and sudden boost on January 7, 2025. Here's why these companies are experiencing tailwinds in ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

Also, Penn settled a lawsuit with the German drug manufacturer BioNTech, which, with Pfizer, made the COVID vaccine using ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...